BSE Live
Mar 24, 16:01Prev. Close
6011.85
Open Price
6139.35
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 24, 15:55Prev. Close
6013.50
Open Price
6090.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
6026.00 (38)
| Key Financial Ratios of Divis Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 63.82 | 59.65 | 46.06 | 41.15 | 32.90 | |
| Diluted EPS (Rs.) | 63.82 | 59.65 | 46.06 | 41.15 | 32.88 | |
| Cash EPS (Rs.) | 74.05 | 66.58 | 51.86 | 45.81 | 36.87 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 268.35 | 228.61 | 192.36 | 163.85 | 137.87 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 268.35 | 228.61 | 192.36 | 163.85 | 137.87 | |
| Dividend / Share(Rs.) | 20.00 | 20.00 | 15.00 | 13.00 | 10.00 | |
| Revenue from Operations/Share (Rs.) | 232.34 | 189.40 | 160.39 | 138.99 | 99.16 | |
| PBDIT/Share (Rs.) | 90.77 | 83.08 | 65.56 | 57.30 | 40.27 | |
| PBIT/Share (Rs.) | 80.54 | 76.14 | 59.77 | 52.63 | 36.24 | |
| PBT/Share (Rs.) | 80.40 | 75.99 | 59.64 | 52.35 | 36.13 | |
| Net Profit/Share (Rs.) | 63.82 | 59.65 | 46.06 | 41.13 | 32.85 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 39.06 | 43.86 | 40.87 | 41.22 | 40.60 | |
| PBIT Margin (%) | 34.66 | 40.20 | 37.26 | 37.86 | 36.54 | |
| PBT Margin (%) | 34.60 | 40.12 | 37.18 | 37.66 | 36.43 | |
| Net Profit Margin (%) | 27.46 | 31.49 | 28.72 | 29.59 | 33.12 | |
| Return on Networth / Equity (%) | 23.78 | 26.09 | 23.94 | 25.10 | 23.82 | |
| Return on Capital Employed (%) | 22.87 | 25.04 | 23.12 | 24.23 | 22.92 | |
| Return on Assets (%) | 18.92 | 20.92 | 19.13 | 19.47 | 18.87 | |
| Total Debt/Equity (X) | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Asset Turnover Ratio (%) | 68.91 | 66.43 | 66.61 | 65.82 | 56.96 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.62 | 3.68 | 3.40 | 3.18 | 3.76 | |
| Quick Ratio (X) | 2.18 | 2.25 | 1.94 | 2.00 | 2.43 | |
| Inventory Turnover Ratio (X) | 2.77 | 2.81 | 2.64 | 2.83 | 2.42 | |
| Dividend Payout Ratio (NP) (%) | 31.34 | 33.53 | 32.56 | 31.60 | 30.44 | |
| Dividend Payout Ratio (CP) (%) | 27.00 | 30.03 | 28.92 | 28.38 | 27.12 | |
| Earnings Retention Ratio (%) | 68.66 | 66.47 | 67.44 | 68.40 | 69.56 | |
| Cash Earnings Retention Ratio (%) | 73.00 | 69.97 | 71.08 | 71.62 | 72.88 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 23,730.92 | 18,153.46 | 13,055.02 | 10,207.03 | 8,967.84 | |
| EV/Net Operating Revenue (X) | 7.69 | 7.22 | 6.13 | 5.53 | 6.82 | |
| EV/EBITDA (X) | 19.70 | 16.46 | 15.00 | 13.42 | 16.80 | |
| MarketCap/Net Operating Revenue (X) | 7.70 | 7.23 | 6.13 | 5.52 | 6.82 | |
| Retention Ratios (%) | 68.65 | 66.46 | 67.43 | 68.39 | 69.55 | |
| Price/BV (X) | 6.67 | 5.99 | 5.11 | 4.68 | 4.90 | |
| Price/Net Operating Revenue | 7.70 | 7.23 | 6.13 | 5.52 | 6.82 | |
| Earnings Yield | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 |
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
12.02.2026
Accumulate Divis Laboratories; target of Rs 6850: Prabhudas Lilladher
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
24.03.2026
24.03.2026
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth